Question 1

What is regulatory writing software?

Accepted Answer

Regulatory writing software is a specialized authoring environment for the documents that make up a regulatory submission: clinical overviews, summaries of clinical safety and efficacy, deficiency responses, briefing documents, protocol amendments, and Module 1 cover letters. It differs from a general word processor by understanding the CTD structure, maintaining linked citations to source data, supporting multi-reviewer workflows with role-based approvals, and preserving an audit trail of every change through final sign-off. Assyro adds AI-assisted drafting on top of these fundamentals.

Question 2

Does Assyro replace regulatory writers?

Accepted Answer

No. Regulatory writing requires scientific judgment, regulatory strategy, and sensitivity to how a specific authority reads specific language. Assyro removes the mechanical work around writing: formatting, citation management, version cleanup, review routing, reference verification. Writers spend their time on the judgment work instead of reformatting a document for the fourth time. In practice, teams using Assyro do not reduce headcount; they shift writer time toward more complex sections and more programs.

Question 3

How much faster is drafting with AI-assisted writing?

Accepted Answer

For document types where the structure and source material are well-defined (clinical overviews drawing from completed study reports, deficiency responses tied to specific FDA questions, Module 2.5 from Module 5 data), teams report 50-70% reductions in time-to-first-reviewable-draft. Final sign-off time depends on how many review cycles the organization runs, which is usually more about process than writing tool. Assyro's review workflow tends to reduce review cycles as well, which compounds the drafting speedup.

Question 4

Is AI-drafted regulatory content FDA-acceptable?

Accepted Answer

FDA does not prohibit AI-assisted drafting. What FDA evaluates is the content itself: scientific accuracy, regulatory adequacy, consistency across modules, supporting evidence. AI-assisted drafting in Assyro is generative in the sense that it produces a first draft, but the output is always traceable to the source documents it cited, and writers and reviewers retain final accountability for every statement. Several sponsors now disclose AI-assisted drafting in submission cover letters; FDA has issued draft guidance on AI use in drug development (2024-2025) that treats authoring tools as standard practice.

Question 5

Can we use Assyro for deficiency response letters?

Accepted Answer

Yes. Deficiency responses (FDA Information Requests, Discipline Review Letters, Complete Response Letters) are one of the highest-value use cases for regulatory writing software because they are time-constrained, evidence-heavy, and often involve cross-functional input. Assyro drafts structured responses that address each FDA question, links supporting data automatically, and routes sections to the relevant CMC, clinical, or statistical reviewer with tracked change history.

Question 6

How does Assyro handle version control during review?

Accepted Answer

Every change is captured with the author, timestamp, section, and rationale in an auditable log. Writers and reviewers see tracked changes inline, and the underlying document has a complete version history rather than a 'draft_v12_FINAL_revised.docx' file chain. Role-based permissions control who can edit, comment, or approve at each stage, and approvals are electronic signatures that meet 21 CFR Part 11 expectations for regulated workflows.

Question 7

Can writers collaborate in real time?

Accepted Answer

Yes. Multiple writers can edit different sections concurrently without the merge conflicts that break Word-based workflows. Sections are locked to the active editor, and changes from other collaborators flow in once committed. Reviewers can comment without blocking the writer, and approval routing runs in parallel where the workflow allows it. Teams that moved from a Word + SharePoint workflow to Assyro typically see a 2-3 day compression on every major document review cycle.

Question 8

Does Assyro integrate with our existing document management system?

Accepted Answer

Yes, for common systems: Veeva Vault (both QualityDocs and Submissions), SharePoint, MasterControl, and direct API for internal systems. Assyro can serve as the writing and review surface while finalized documents are published into the DMS of record, or it can serve as the system of record for the submission writing workflow with the DMS handling adjacent quality documents. The integration pattern is configured during implementation based on the team's existing data architecture.

Regulatory Writing Software

How Regulatory Writing Fits the Submission Workflow

Draft a Clinical Overview in Hours, Not Weeks

Link Every Claim to Its Evidence Automatically

Reduce Review Cycles from 4 to 1

Reuse Approved Language Across Indications and Filings

Controls and Traceability for Regulatory Writing

Keep Regulatory Writing Audit-Ready

Scale Across Programs Without Adding Complexity

Questions About Regulatory Writing

See Regulatory Writing in a Live Submission Workflow.